Institutional investors purchased a net $19.8 million shares of ELN during the quarter ended December 2012, and now own 66.60% of the total float, a percentage that is typical for companies in the Biotechnology industry.
| Mutual fund holders | 33.56% |
| Other institutional | 33.04% |
| Individual stakeholders | -- |